Contribution of disturbed iron metabolism to the pathogenesis of Parkinson's disease

Future Neurology

Volumn 3, Issue 4, 2008, Pages 447-461

  Berg, Daniela ^a   Riederer, Peter ^b,c   Gerlach, Manfred ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research   (Germany)

Author keywords

Blood brain barrier; Ferritin; Genetic causes; Iron homeostasis; Iron regulatory systems; MRI; Neuromelanin; Oxidative stress; Parkinson's disease; Transcanial sonography

Indexed keywords

6 FLUORODOPA F 18; DEFEROXAMINE; FERRITIN; HEMOSIDERIN; IRON; IRON BINDING PROTEIN; LACTOFERRIN; NEUROLEPTIC AGENT; OXIDOPAMINE; PARKIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; VERAPAMIL;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; DIFFERENTIAL DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DOPPLER ECHOGRAPHY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IRON METABOLISM; IRON STORAGE; LEWY BODY; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NITROSATIVE STRESS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REVIEW; SUBSTANTIA NIGRA;

EID: 47249087761     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.4.447     Document Type: Review

References (162)

1. Tan EK: The role of common genetic risk variants in Parkinson disease. Clin. Genet. 72(5), 387-393 (2007).
2. Edwards TM, Myers JP: Environmental exposures and gene regulation in disease etiology. Environ. Health Perspect. 115(9), 1264-1270 (2007).
3. Elbaz A, Tranchant C: Epidemiologic studies of environmental exposures in Parkinson's disease. J. Neurol. Sci. 262(1-2), 37-44 (2007).
4. Elbaz A, Dufouil C, Alperovitch A: Interaction between genes and environment in neurodegenerative diseases. C R Biol. 330(4), 318-328 (2007).
5. Riederer P, Rausch WD, Schmidt B et al.: Biochemical fundamentals of Parkinson's disease. Mt Sinai J. Med. 55(1), 21-28 (1988).
6. Riederer P, Sofic E, Rausch WD et al.: Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52(2), 515-520 (1989).
7. Sofic E, Riederer P, Heinsen H et al.: Increased iron (III) and total iron content in post moirtem substantia nigra of parkinsonian brain. J. Neural Transm. 74(3), 199-205 (1988).
8. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB: Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56(3), 978-982 (1991).
9. Gerlach M, Ben-Shachar D, Riederer P, Youdim, MB: Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63(3), 793-807 (1994).
10. Berg D, Gerlach M, Youdim MB et al.: Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79(2), 225-236 (2001).
11. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P: The relevance of iron in the pathogenesis of Parkinson's disease. Ann. NY Acad. Sci. 1012, 193-208 (2004).
12. Gerlach M, Double KL, Youdim MB, Riederer P: Potential sources of increased iron in the substantia nigra of parkinsonian patients. J. Neural Transm. Suppl. 70, 133-142 (2006).
13. Morawski M, Meinecke C, Reinert T et al.: Determination of trace elements in the human substantia nigra. Nucl. Instrum. Methods Phys. Res. B. 231, 224-228 (2005).
14. Oakley AE, Collingwood JF, Dobson J et al.: Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68(21), 1820-1825 (2007).
15. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB: Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2(4), 327-340 (1990).
16. Jellinger V, Kienzl E, Rumpelmair G et al.: Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 59(3), 1168-1171 (1992).
17. Yoshida T, Tanaka M, Sotomatsu A, Hirai S, Okamoto K: Activated microglia cause iron-dependent lipid peroxidation in the presence of ferritin. Neuroreport 9(9), 1929-1933 (1998).
18. Schipper HM, Vininsky R, Brull R, Small L, Brawer JR: Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp. Neurol. 152(2), 188-196 (1998).
19. Warmurth-Metz M, Naumann M, Csoti I, Solymosi L: Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch. Neurol. 58(7), 1076-1079 (2001).
20. Schenck JF: Magnetic resonance imaging of brain iron. J. Neurol. Sci. 207(1-2), 99-102 (2003).
21. Drayer BP, Olanow W. Burger P, Johnson GA, Herfkens R, Riederer S: Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 159(2), 493-498 (1986).
22. Norfray JF, Chiaradonna NL, Heiser WJ et al.: Brain iron in patients with Parkinson disease: MR visualization using gradient modification. Am. J. Neuroradiol. 9(2), 237-240 (1988).
23. 2 values and iron levels. J. Neurol. Neurosurg. Psychiatr. 52(1), 108-111 (1989).
24. Bartzokis G, Cummings JL, Markham CH et al.: MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 17(2), 213-222 (1999).
25. 2 relaxation time in patients with Parkinson's disease. Neurology 43 (4), 697-700 (1993).
26. 2-Weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol. India 52(3), 332-337 (2004).
27. 2*-weighted MRI at 3 Tesla. Magn. Reson. Med. 32(3), 335-341 (1994).
28. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA: Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45(6), 1138-1143 (1995).
29. Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K: The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-rccovery MR findings. Am. J. Neuroradiol. 23(10), 1747-1756 (2002).
30. Hutchinson M, Raff U, Lebedev S: MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM). Neuroimage 20(3), 1899-1902 (2003).
31. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD: Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123(Pt 12), 2423-2431 (2000).
32. Michaeli S, Oz G, Sorce DJ et al.: Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov. Disord. 22(3), 334-340 (2007).
33. Barrzokis G, Cummings J, Perlman S, Hance DB, Mintz J: Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56(5), 569-574 (1999).
34. Haacke EM, Ayaz M, Khan A et al.: Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs abnormal iron content in the brain. J. Magn. Reson. Imaging 26(2), 256-264 (2007).
35. Brass SD, Chen NK, Mulkern RV, Bakshi R: Magnetic resonance imaging of iron deposition in neurological disorders. Top. Magn, Reson. Imaging 17(1), 31-40 (2006).
36. Kosta P. Argyropoulou MI, Markoula S, Konitsiotis S: MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J. Neurol. 253(1), 26-32 (2006).
37. Stankiewicz J, Panter SS, Neema M, Arora A, Batt CE, Bakshi R: Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 4(3), 371-386 (2007).
38. Berg D, Siefker C, Becker G: Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 248(8), 684-689 (2001).
39. Walter U, Wittstock M, Benecke R, Dressler D: Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J. Neural Transm. 109(2), 191-196 (2002).
40. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K: Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45(1), 182-184 (1995).
41. 123IFP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 129(Pt 5), 1188-1193 (2006).
42. Ressner P, Skoloudik D, Hlustik P, Kanovsky P: Hyperechogenicity of the substantia nigra in Parkinson's disease. J. Neuroimaging 17(2), 164-167 (2007).
43. Okawa M, Miwa H, Kajimoto Y et al.: Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern. Med. 46(18), 1527-1531 (2007).
44. Huang YW, Jeng JS, Tsai CF, Chen LL, Wu RM: Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease. Mov. Disord. 22(4), 550-555 (2007).
45. Tsai CF, Wu RM, Huang YW, Chen LL, Yip PK, Jeng JS: Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. J. Neurol. 254(4), 501-507 (2007).
46. Gaenslen A, Unmuth B, Godau, J, Liepelt I, Di Santo A, Schweitzer KJ: Prospective evaluation of the specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease. Lancet Neurol. (2008) (In Press).
47. Berg D, Grote C, Rausch WD et al.: Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med. Biol. 25(6), 901-904 (1999).
48. Berg D, Becker G, Zeiler B et al.: Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53(5), 1026-1031 (1999).
49. Berg D, Roggendorf W, Schroder U et al.: Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 59(6), 999-1005 (2002).
50. Zecca L, Berg D, Arzberger T et al.: In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov. Disord. 20(10), 1278-1285 (2005).
51. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G: Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56(1), 13-17 (2001).
52. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G: Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol. Psychiatry 50(6), 463-467 (2001).
53. Thomas M, Hayflick SJ, Jankovic J: Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov. Disord. 19(1), 36-42 (2004).
54. Kaur D, Yantiri F, Rajagopalan S et al.: Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37(6), 899-909 (2003).
55. Ruprecht-Dorfler P. Berg D, Tucha O et al.: Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. Neuroimage 18(2), 416-422 (2003).
56. Felletschin B, Bauer P, Walter U et al.: Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci. Lett. 352(1), 53-56 (2003).
57. Deplazes J, Schobel K, Hochstrasser H et al.: Screening for mutations of the IRP2 gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. J. Neural Thansm. 111(4), 515-521 (2004).
58. Hochstrasser H, Bauer P, Walter U et al.: Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63(10), 1912-1917 (2004).
59. Akbas N, Hochstrasser H, Deplazes J et al.: Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci. Lett. 407(1), 16-19 (2006).
60. Berg D, Hochstrasser H, Schweitzer KJ, Riess O: Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox. Res. 9(1), 1-13 (2006).
61. Klomp LW, Gitlin JD: Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum. Mol. Genet. 5(12), 1989-1996 (1996).
62. Curtis AR, Fey C, Morris CM et al.: Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28(4), 350-354 (2001).
63. Kohno S, Miyajima H, Takabashi Y, Inoue Y: Aceruloplasminemia with a novel mutation associated with parkinsonism. Neurogenetics 2(4), 237-238 (2000).
64. Bosio S, De Gobbi M, Roetto A et al.: Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 100(6), 2246-2248 (2002).
65. Thompson K, Menzies S, Muckenthaler M et al.: Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J. Neurosci. Res. 71(1), 46-63 (2003).
66. LaVaute T, Smith S, Cooperman S et al.: Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Mat. Genet. 27(2), 209-214 (2001).
67. Borie C, Gasparini F, Verpillat P et al.: Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 249(7), 801-804 (2002).
68. Costa-Mallen P, Checkoway H, Zabeti A et al.: The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 147B(2), 216-222 (2007).
69. Haaxma CA, Bloem BF, Borm GF et al.: Gender differences in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 78(8), 819-824 (2007).
70. Bartzokis G, Tishler TA, Lu PH et al.: Brain ferritin iron may influence age-and gender-related risks of neurodegeneration. Neurobiol. Aging 28(3), 414-423 (2007).
71. Xu X, Wang Q, Zhang M: Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 40(1), 35-42 (2008).
72. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW: Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660(1), 8-18 (1994).
73. Kortekaas P, Leenders KL, van Oostrom JC et al.: Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57(2), 176-179 (2005).
74. Tanner CM, Ottman R, Goldman SM et al.: Parkinson disease in twins: an etiologic study. JAMA 281(4), 341-346 (1999).
75. Lan J, Jiang DH: Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104(6-7), 649-660 (1997).
76. Kaur D, Peng J, Chinta SJ et al.: Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol. Aging 28(6), 907-913 (2007).
77. 2+ influx, and cAMP signaling. J. Neurosci. 27(46), 12611-12622 (2007).
78. Dick FD, De Palma G, Ahmadi A et al.: Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup. Environ. Med. 64(10), 666-672 (2007).
79. Dick FD, De Palma G, Ahmadi A et al.: Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup. Erviron. Med. 64(10), 673-680 (2007).
80. Faucheux BA, Nillesse N, Damier P et al.: Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 92(21), 9603-9607 (1995).
81. 125I-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. Brain Res. 749(1), 170-174 (1997).
82. Morris CM, Candy JM, Omar S, Bloxham CA, Edwardson JA: Transferrin receptors in the parkinsonian midbrain. Neuropathol. Appl. Neurobiol. 20(5), 468-472 (1994).
83. Dexter DT, Carayon A, Vidailhet M et al.: Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55(1), 16-20 (1990).
84. Logroscino G, Marder K, Graziano J et al.: Dietary iron, animal fats, and risk of Parkinson's disease. Mov. Disord. 13(Suppl. 1), 13-16 (1998).
85. Torsdottir G, Kristinsson J, Sveinbjornsdottir S, Snaedal J, Johannesson T: Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol. Toxicol. 85(5), 239-243 (1999).
86. Leveugle B, Faucheux BA, Bouras-C et al.: Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol. 91(6), 566-572 (1996).
87. Hallgren B, Sourander P: The effect of age on the non-haem iron in the human brain. J. Neurochem. 3(1), 41-51 (1958).
88. Dwork AJ, Lawler G, Zybert PA et al.: An autoradiographic study of the uptake and distribution of iron by the brain of the young rat. Brain Res. 518(1-2), 31-39 (1990).
89. Mann VM, Cooper JM, Daniel SE et al.: Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36(6), 876-881 (1994).
90. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ: Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31(2), 327-335 (1992).
91. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P: A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Aizheimer's diseased brains. J. Neurochem. 65(2), 717-724 (1995).
92. Griffiths PD, Dobson BR, Jones GR, Clarke DT: Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended x-ray absorption fine structure and cryo-electron microscopy. Brain 122(Pt 4), 667-673 (1999).
93. Meneghini R: Iron homeostasis, oxidative stress, and DNA damage. Free Radic. Biol. Med. 23(5), 783-792 (1997).
94. Hu J, Connor JR: Demonstration and characterization of the iron regulatory protein in human brain. J. Neurochem. 67(2), 838-844 (1996).
95. Smith MA, Wehr K, Harris PL, Siedlak SL, Connor JR, Perry G: Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res. 788(1-2), 232-236 (1998).
96. Boyer RF, Grabill TW, Petrovich RM: Reductive release of ferritin iron: a kinetic assay. Anal. Biochem. 174(1), 17-22 (1988).
97. Monteiro HP, Winterbourn CC: 6-hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38(23), 4177-4182 (1989).
98. Lapenna D, Degioia S, Ciofani G, Cuccurullo F: Captopril induces iron release from ferritin and oxidative stress. J. Pharm. Pharmacol. 47, 59-61 (1995).
99. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M: In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70(6), 2492-2499 (1998).
100. Biemond P, van Eijk HG, Swaak AJ, Koster JF: Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. Possible mechanism in inflammation diseases. J. Clin. Invest. 73(6), 1576-1579 (1984).
101. Reif DW, Simmons RD: Nitric oxide mediates iron release from ferritin. Arch. Biochem. Biophys. 283(2), 537-541 (1990).
102. Youdim MB, Ben-Shachar D, Riederer P: The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8(1), 1-12 (1993).
103. Yoshida T, Tanaka M, Sotomatsu A, Hirai S: Activated microglia cause superoxide-mediated release of iron from ferritin. Neurosci. Lett. 190(1), 21-24 (1995).
104. 2 oxidation of dopamine. J. Med. Chem. 38(6), 917-922 (1995).
105. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB: Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. Suppl. 46, 297-314 (1995).
106. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB: Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316(3), 160-168 (1996).
107. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK: The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 18(11), 1175-1177 (1993).
108. Connor JR, Menzies SL, St Martin SM, Mufson EJ: Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27(4), 595-611 (1990),
109. Double KL, Gerlach M, Youdim MB, Riederer P: Impaired iron homeostasis in Parkinson's disease. J. Neural Transm. Suppl. 60, 37-58 (2000).
110. Fedorow H, Pickford R, Hook JM et al.: Dolichol is the major lipid component of human substantia nigra neuromelanin. J. Neurochem. 92(4), 990-995 (2005).
111. Lopiano L, Digilio G, Fasano M et al.: Iron and neuromelanin in Parkinson's disease. J. Neural Transm. 106, 24 (1999).
112. Gerlach M, Trautwein AX, Zecca L, Youdim MB, Riederer P: Mossbauer spectroscopic studies of purified human neummelanin isolated from the substantia nigra. J. Neurochem. 65 (2), 923-926 (1995).
113. Double KL, Gerlach M, Schunemann V et al.: Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66(3), 489-494 (2003).
114. Good PF, Olanow CW, Perl DP: Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593(2), 343-346 (1992).
115. Zecca. L, Shima T, Stroppolo A et al.: Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 73(2), 407-415 (1996).
116. Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF: The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 134(Suppl.) 69-78 (1995).
117. Double KL, Riederer P, Gerlach M: Significance of neuromelanin for neurodegeneration in Parkinson's disease. Drug News Perspect. 12, 333-340 (1999).
118. Schipper HM: Heme oxygenase expression in human central nervous system disorders. Free Radic. Biol, Med. 37(12), 1995-2011 (2004).
119. Polymeropoulos; MH, Lavedan C, Leroy E et al.: Mutation in the γ-symiclein gene identified in families with Parkinson's disease. Science 276(5321), 2045-2047 (1997).
120. Kruger R, Kuhn W, Muller T et al.: Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18(2), 106-108 (1998).
121. Singleton AB, Fairer M, Johnson J et al.: α-synuclein locus triplication causes Parkinson's disease, Science 302(5646), 841 (2003).
122. Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B: Magnesium-inhibits spontaneous and iron-induced aggregation of α-synuclein. J. Biol Chem. 277(18), 16116-16123 (2002).
123. Hashimoto M, Rockenstein E, Crews L, Masliah E: Role ofprotein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 4(1-2), 21-36 (2003).
124. Giasson BI, Duda JE, Murray IV et al.: Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290(5493), 985-989 (2000).
125. Munch G, Luth HJ, Wong A et al.: Crosslinking of α-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J. Chem. Neuroanat. 20(3-4), 253-257 (2000).
126. 2. J. Neurochem. 84(5), 1128-1142 (2003).
127. Bharathi, Indi SS, Rao KS: Copper- and iro-induced differential fibril formation in α-synuclein: TEM study. Neurosci. Lett. 424(2), 78-82 (2007).
128. Uversky VN: Neuropathology, biochemistry, and biophysics of α-synuclein aggregation. J. Neurochem. 1030), 17-37 (2007).
129. Cole NB, Murphy DD, Lebowitz J, Di Noto L, Levine RL, Nussbaum RL, Metal-catalyzed oxidation of α-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J. Biol. Chem. 280(10), 9678-9690 (2005).
130. Jenner P, Olanow CW: Understanding cell death in Parkinson's disease. Ann. Neurol. 44(3 Suppl. 1), S72-S84 (1998).
131. Gaeta A, Hider RC: The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146(8), 1041-1059 (2005).
132. Castellani RJ, Siedlak SL, Perry G, Smith MA: Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuroparhol (Berl) 100(2), 111-114 (2000).
133. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D: α-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. 30(10), 1163-1170 (2001).
134. Junn, E, Mouradian MM: Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320(3), 146-150 (2002).
135. Wang C, Ko HS, Thomas B et al.: Stress-induced alterations in parkin solubility promote Parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 14(24), 3885-3897 (2005).
136. Jimenez Del Rio M, Moreno S, Garda-Ospina G et al.: Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis. Mov. Disord. 19(3), 324-330 (2004).
137. Yao D, Gu Z, Nakamura T et al.: Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl Acad. Sci. USA 101(29), 10810-10814 (2004).
138. Lipton SA, Nakamura T, Yao D, Shi ZQ, Uehara T, Go Z: Comment on 'S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function'. Science 308(5730), 1870; author reply 1870 (2005).
139. Pawlyk AC, Giasson BI, Sampathu DM et al.: Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem. 278(48), 48120-48128 (2003).
140. Nishikawa K, Li H, Kawamura R et al.: Alterations of structure and hydrolasc activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 304(1), 176-183 (2003).
141. Choi J, Levey AI, Weintraub ST et al.: Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279(13), 13256-13264 (2004).
142. Chung KK, Thomas B, Li X et al.: S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304(5675), 1328-1331 (2004).
143. Ciechanover A, Brundin P: The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40(2), 427-446 (2003).
144. Zhou W, Zhu M, Wilson MA, Petsko GA, Fink AL: The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein. J. Mol. Biol. 356(4), 1036-1048 (2006).
145. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A: DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol. 2(11), E362 (2004).
146. Mizuno Y, Ohta S, Tanaka M et al.: Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163(3), 1450-1455 (1989).
147. Reichmann H, Janetzky B: Mitochondrial dysfunction - a pathogenetic factor in Parkinson's disease. J. Neurol. 247(Suppl. 2), II63-II68 (2000).
148. Beal MF: Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr. 36(4), 381-386 (2004).
149. Liu Y, Fiskurn G, Schubert D: Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80(5), 780-787 (2002).
150. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS: Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. NY Acad. Sci. 962, 318-331 (2002).
151. Shamoto-Nagai M, Maruyama W, Kato Y et al.: An inhibitor ofmitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J. Neurosm Res. 74(4), 589-597 (2003).
152. + anakigs acting on mitochomdria and inducing neurodegeneration. Curr. Med. Chem 10(23), 2507-2516 (2003).
153. Go M, Cooper JM, Taanman JW, Schapira AH: Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44(2), 177-186 (1998).
154. Carreras MC, Franco MC, Peralta JG, Poderoso JJ: Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol Aspects Med. 25(1-2), 125-139 (2004).
155. Naoi M, Maruyama W, Akao Y, Zhang J, Parvtz H: Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons. Toxicology 153 (1-3), 123-141 (2000).
156. Davis GC, Williams AC, Markey SP et al.: Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1(3), 249-254 (1979).
157. Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587), 979-980 (1983).
158. Chan TS, Teng S, Wilson JX, Galati G, Khan S, O'Brien PJ: Coenzyme Q cytoprotective mechanisms for mitochondrial complex. I cytopathies involves NAD(P)H: quinone oxidoreductase 1 (NQO1). Free Radic. Res. 36(4), 421-427 (2002).
159. Sherer TB, Betarbet R, Stout AK et al.: An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J. Neurosci. 22(16), 7006-7015 (2002).
160. Fiskum G, Starkov A, Polster BM, Chinopoulos C: Mitocliondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann. NY Acad. Sci. 991, 111-119 (2003).
161. Kanthasamy AG, Kitazawa M, Kaul S et al.: Proteolytic activation of proapoptotic kinase PKCδ is regulated by overexpression of Bcl-2: implications for oxidative stress and environmental factors in Parkinson's disease. Ann. NY Acad Sci. 1010, 683-686 (2003).
162. Rossi L, Lombardo MF, Ciriolo MR, Rotilio, G: Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance. Neurochem. Res. 29(3), 493-504 (2004).